SAN DIEGO—Cytiva has launched its Sefia next-generation manufacturing platform, with the goal of helping drug developers and larger healthcare providers accelerate their production of chimeric antigen ...

Under the ongoing collaboration Remedy Cell’s personnel, along with Pluri’s Contract Development and Manufacturing Organization (“CDMO”) division (PluriCDMO™), have successfully completed the full ...

Editor’s note: BioPharma Dive, as part of Emerging Biotech Weekly, is taking a closer look at competitive areas of startup activity. We aim to give an overview of the companies developing a new ...

Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...

A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s Cellares has passed another major production milestone. Cellares’ automated ...

Achieving the manufacturing throughput necessary to satisfy expected patient demand is dependent on several factors, including decreasing reliance on large, expensive manufacturing facilities; ...

Cellular immunotherapy—for example, Chimeric Antigen Receptor (CAR)-T cell therapy—has shown great efficacy in treating various hematologic malignancies. CAR-T therapy has undergone notable changes, ...

The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...

DUBLIN--(BUSINESS WIRE)--The "Point-of-Care Cell and Gene Therapy Manufacturing Market - A Global and Regional Analysis: Focus on Technology, Therapeutic Area, End User, and Regional Analysis - ...

CAPEX investment for setting up the PERC production is higher in the case of a MLD setup. Image: Fraunhofer ISE A solar cell manufacturing plant can reduce water consumption by up to 79% with existing ...